Myriad Genetics, Clairity, and MagView Launch Integrated AI and Genetic Breast Cancer Risk Platform
Myriad Genetics, Clairity, and MagView have collaborated to launch an integrated AI and genetic risk platform for breast cancer. This platform combines Clairity's mammogram-based risk assessment, Myriad's MyRisk Hereditary Cancer Test, and MagView's imaging software to identify high-risk women, enabling earlier interventions and streamlining clinical workflows. The announcement was made via GlobeNewswire on November 25, 2025.
Myriad Genetics Inc. has announced a joint collaboration with Clairity and MagView to launch the first integrated AI and genetic risk platform for personalized breast health. The partnership combines Clairity’s FDA-authorized mammogram-based risk assessment, Myriad’s MyRisk Hereditary Cancer Test with RiskScore, and MagView’s breast imaging software into one unified system. This integrated platform aims to identify more women at high risk for breast cancer, enabling earlier and more personalized interventions while streamlining clinical workflows. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592290-en) on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
